Selectis Health (GBCS) Cash & Equivalents (2010 - 2025)

Selectis Health (GBCS) has 16 years of Cash & Equivalents data on file, last reported at $1.0 million in Q4 2025.

• Quarterly Cash & Equivalents rose 48.7% year-over-year to $1.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.0 million (up 48.7% YoY) and the FY2025 annual result came in at $1.0 million, up 48.7% from the prior year.
• Cash & Equivalents climbed to $1.0 million in Q4 2025 per GBCS's latest filing, from $417125.0 in the prior quarter.
• The five-year high for Cash & Equivalents was $3.1 million in Q3 2023, with the low at $410866.0 in Q1 2021.
• Average Cash & Equivalents over 5 years is $1.0 million, with a median of $834955.0 recorded in 2022.
• Year-over-year, Cash & Equivalents sank 80.95% in 2021 and jumped 269.3% in 2023.
• Selectis Health's Cash & Equivalents stood at $853656.0 in 2021, then surged by 183.09% to $2.4 million in 2022, then slumped by 38.57% to $1.5 million in 2023, then plunged by 54.17% to $680332.0 in 2024, then soared by 48.7% to $1.0 million in 2025.
• Business Quant data shows GBCS's Cash & Equivalents at $1.0 million in Q4 2025, $417125.0 in Q3 2025, and $559983.0 in Q2 2025.